Bovine colostrum ameliorates diarrhea in infection with diarrheagenic Escherichia coli, shiga toxin-producing E. Coli, and E. coli expressing intimin and hemolysin.

BACKGROUND Diarrheagenic Escherichia coli may cause serious extraintestinal complications, but there is no specific treatment. METHODS Patients with diarrhea caused by diarrheagenic E. coli, specifically Shiga toxin-producing E. coli and E. coli-expressing intimin and enterohemorrhagic E. coli-hemolysin were treated by administration of pooled bovine colostrum, rich in antibodies to Shiga toxin and enterohemorrhagic E. coli-hemolysin, in a placebo-controlled, double-blind study. Symptom resolution and fecal excretion of infecting strains were assessed. RESULTS No side effects were attributable to colostrum. Stool frequencies in the group treated with bovine colostrum were significantly reduced compared with those in the placebo group. No effect of therapy on the carriage of the pathogens or on complications of the infection could be demonstrated. CONCLUSIONS Bovine colostrum is well tolerated and diminishes frequency of loose stools in children with E. coli-associated diarrhea. A prospective study should be conducted among a larger number of children with Shiga toxin-producing E. coli identified early in illness, to determine the effectiveness of colostrum therapy.

[1]  H. Karch,et al.  Non-O157:H7 pathogenic Shiga toxin-producing Escherichia coli: phenotypic and genetic profiling of virulence traits and evidence for clonality. , 1999, The Journal of infectious diseases.

[2]  R. Salmon,et al.  Risk factors for and prevention of sporadic infections with vero cytotoxin (shiga toxin) producing Escherichia coli 0157 , 1998, The Lancet.

[3]  James P. Nataro,et al.  Diarrheagenic Escherichia coli , 1998, Clinical Microbiology Reviews.

[4]  B. Bell,et al.  Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. , 1997, Pediatrics.

[5]  H. Karch,et al.  Acute and chronic diarrhoea and abdominal colic associated with enteroaggregative Escherichia coli in young children living in western Europe , 1997, The Lancet.

[6]  T. Whittam,et al.  Genetic and phenotypic analysis of Escherichia coli with enteropathogenic characteristics isolated from Seattle children. , 1997, The Journal of infectious diseases.

[7]  G. Davidson Passive protection against diarrheal disease. , 1996, Journal of pediatric gastroenterology and nutrition.

[8]  D. Busch,et al.  Diarrhea in young children associated with Escherichia coli non-O157 organisms that produce Shiga-like toxin. , 1996, The Journal of pediatrics.

[9]  R. Welch,et al.  Characterization of an RTX toxin from enterohemorrhagic Escherichia coli O157:H7 , 1996, Infection and immunity.

[10]  A. Caprioli,et al.  Genotyping of Shiga-like toxin genes in non-O157 Escherichia coli strains associated with haemolytic uraemic syndrome. , 1995, Journal of medical microbiology.

[11]  H. Karch,et al.  Long-term shedding and clonal turnover of enterohemorrhagic Escherichia coli O157 in diarrheal diseases , 1995, Journal of clinical microbiology.

[12]  L. Beutin,et al.  Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933 , 1995, Infection and immunity.

[13]  E. Avner,et al.  Lessons learned in the management of hemolytic uremic syndrome in children. , 1995, Journal of pediatric surgery.

[14]  P. Tarr Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Heesemann,et al.  Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. , 1994, Journal of medical microbiology.

[16]  H. Lior,et al.  Epidemic Escherichia coli O157: H7 gastroenteritis and hemolytic-uremic syndrome in a Canadian Inuit community: Intestinal illness in family members as a risk factor , 1994 .

[17]  M. Levine,et al.  Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. , 1993, The Journal of clinical investigation.

[18]  G. Delage,et al.  Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. , 1992, The Journal of pediatrics.

[19]  H. Brüssow,et al.  Field Trial of an Infant Formula Containing Anti‐rotavirus and Anti‐Escherichia coli Milk Antibodies from Hyperimmunized Cows , 1992, Journal of pediatric gastroenterology and nutrition.

[20]  J. Kaper,et al.  Oligonucleotide probe for detection of the enteropathogenic Escherichia coli (EPEC) adherence factor of localized adherent EPEC , 1990, Journal of clinical microbiology.

[21]  J. Yu,et al.  A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Wells,et al.  Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. , 1990, The Journal of pediatrics.

[23]  S. Ostroff,et al.  Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. , 1989, JAMA.

[24]  J. Carlson,et al.  A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. , 1987, The New England journal of medicine.

[25]  H. Karch,et al.  Growth of Escherichia coli in the presence of trimethoprim-sulfamethoxazole facilitates detection of Shiga-like toxin producing strains by colony blot assay , 1986 .

[26]  A. Cunningham Morbidity in breast-fed and artificially fed infants. II. , 1977, The Journal of pediatrics.